Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Operating Expenses (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Operating Expenses for 7 consecutive years, with $42.4 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 29.9% to $42.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $209.3 million through Dec 2025, down 23.39% year-over-year, with the annual reading at $209.3 million for FY2025, 23.39% down from the prior year.
  • Operating Expenses hit $42.4 million in Q4 2025 for Allogene Therapeutics, down from $44.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $99.1 million in Q1 2023 to a low of $42.4 million in Q4 2025.
  • Historically, Operating Expenses has averaged $72.0 million across 5 years, with a median of $71.7 million in 2021.
  • Biggest five-year swings in Operating Expenses: surged 30.4% in 2022 and later tumbled 37.44% in 2025.
  • Year by year, Operating Expenses stood at $73.9 million in 2021, then soared by 30.4% to $96.4 million in 2022, then dropped by 11.71% to $85.1 million in 2023, then fell by 28.94% to $60.5 million in 2024, then dropped by 29.9% to $42.4 million in 2025.
  • Business Quant data shows Operating Expenses for ALLO at $42.4 million in Q4 2025, $44.9 million in Q3 2025, and $56.8 million in Q2 2025.